🇺🇸 FDA
Patent

US 7718629

Compositions and methods for inhibiting expression of Eg5 gene

granted A61PA61P35/00A61P43/00

Quick answer

US patent 7718629 (Compositions and methods for inhibiting expression of Eg5 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon May 13 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue May 18 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 13 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61P, A61P35/00, A61P43/00